Upstream Bio Reports Third Quarter 2026 Financial Results and Highlights Continued Progress
– Company plans to initiate Phase 3 trials in both severe asthma and CRSwNP in the first quarter of 2027 –
– Company plans to initiate Phase 3 trials in both severe asthma and CRSwNP in the first quarter of 2027 –